Mineralys Therapeutics, Inc.
MLYS
$25.64
-$0.45-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -457.08% | 6.80% | 34.14% | 34.45% | -5.51% |
| Total Depreciation and Amortization | -68.75% | -60.00% | -13.33% | 36.36% | 77.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8,622.55% | -26.01% | -40.07% | 706.79% | 9,196.00% |
| Change in Net Operating Assets | -47.31% | 65.01% | 65.78% | -19.55% | -0.64% |
| Cash from Operations | -7.91% | 13.23% | 43.32% | 42.47% | -0.08% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -331.94% | 51.61% | -223.82% | -288.98% | -654.30% |
| Cash from Investing | -331.94% | 51.61% | -223.84% | -289.07% | -654.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,386.04% | -87.18% | 70,707.30% | 737,942.50% | 7,383.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,091.49% | 90.00% | -548.94% | 29.27% | 83.45% |
| Cash from Financing | 2,374.46% | -87.18% | 107,345.56% | 29,518,900.00% | 6,567.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 140.32% | -218.12% | -365.66% | 293.67% | -180.20% |